Hemophilia In Transition: Can Next-Gen Products Wake A Sleepy Market?
The hemophilia market could be about to undergo a wave of innovation not seen since the introduction of recombinant factor 20 years ago in response to a crisis in contaminated plasma products. Over the next three years, long-acting factor products may have an even more transformative effect on the market, reshuffling segment shares, moving patients to prophylactic use, and expanding an already substantial global market. But will the improvements be enough to sway providers and payors?
You may also be interested in...
Biogen Idec will price its new hemophilia B drug Alprolix on par with older medicines like Pfizer’s Benefix on an annual basis despite the drug’s dosing advantage. The decision comes as high drug prices have come under increased scrutiny from payers and U.S. legislators.
While planning to split into two companies, one focused on its successful hemophilia franchise, Baxter fully acquires Phase I/II gene therapy program for hemophilia B. Baxter has been seeking ways to bolster its hemophilia business in the face of coming competition from the likes of Biogen Idec.
uniQure Grants Chiesi Select Commercial Rights For The EU’s First Approved Gene Therapy Glybera And Hemo B Gene Therapy
uniQure has licensed commercial rights covering Europe and select emerging markets to Italy’s Chiesi for first-to-market gene therapy Glybera and a developmental hemophilia B product. The Dutch biopharma is writing the book on pricing and commercialization, regulatory approval, and market access strategy for gene therapy.